This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Get Jim Cramer's picks for 2006.

NeoPharm (NEOL) was the best-performing drug stock Tuesday after an independent panel recommended the continuation of a phase III trial using its cintredekin besudotox to treat brain cancer. The decision was significant news in a trial where 160 of about 300 enrolled patients are expected to succumb to their illness by the end of the second quarter of 2006. NeoPham's drug is a recombinant protein composed of a tumor-targeting molecule and a cytotoxic agent and is delivered via catheters placed in areas with microscopic tumor spread or that are at risk of tumor spread. NeoPharm shares were up 49% to $11.81.

Shares of Guidant (GDT) fell after the company issued disappointing earnings guidance and disclosed the receipt of a warning letter from the Food and Drug Administration. The pacemaker company, which is the subject of two competing takeover offers, said late Friday that fourth-quarter earnings would trail analysts' estimates due to the impact of several high-profile pacemaker malfunctions on consumer tastes. It also said it received a warning letter from the FDA regarding a manufacturing plant in Wisconsin. The letter, which focused on quality control practices, should not result in a material impact on the company's financial results, Guidant said. Recently, the shares were down 3.3% to $64.79.

The developments didn't sway Boston Scientific (BSX) from its resolve to buy Guidant under the $25 billion takeover offer it proffered last month. A Boston Scientific spokesman told Reuters: "We continue to move forward with our due diligence with the goal of reaching a definitive agreement with Guidant." Boston Scientific's shares were down 2.5% to $25.20 while shares of Johnson & Johnson (JNJ), another suitor, lost 0.7% to $60.67.

Pfizer (PFE - Get Report) said it invested $50 million in Perlegen Sciences, a former Affymetrix (AFFX - Get Report) unit that does genomics research. Pfizer bought a 12% stake in the company through the purchase of preferred stock and agreed to buy up to $25 million more if Perlegen goes public in 2006. The two companies have been research partners since December 2002, when Pfizer used Perlegen's DNA sample preparation and other products to discover genes associated with common diseases and identify genetic markers.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ABI $22.98 1.01%
AFFX $10.38 0.00%
BMY $67.48 0.00%
NTRI $24.00 0.00%
PFE $33.37 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs